Size Matters: Novartis Says Vaccines are for Big Manufacturers, Marketers

The vaccine business is made-to-order for Big Pharma. That's how Novartis is portraying the business to the financial community-a good growing environment if you can afford to reach scale. One of Novartis' partners in development, the Austrian firm Intercell, has also become a hot performer based on its strong piipeline of projects. Maybe there is room for both large and small.